Clinical Analysis and Risk Factors of Bronchiolitis Obliterans After Mycoplasma Pneumoniae Pneumonia.
bronchiolitis obliterans
children
mycoplasma pneumoniae pneumonia
post-infectious bronchiolitis obliterans
risk factors
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
04
2022
accepted:
12
07
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
5
8
2022
Statut:
epublish
Résumé
Severe mycoplasma pneumoniae (MP) pneumonia can cause bronchiolitis obliterans (BO). In order to improve the prognosis of BO, it is necessary to grasp the clinical characteristics and risk factors of BO after severe MP pneumonia and intervene as soon as possible. This study retrospectively analyzed the clinical data of 110 patients with severe MP pneumonia, and divided them into BO group (22 cases) and non-BO group (88 cases). The clinical characteristics of BO group were analyzed, and the clinical data of two groups were compared to identify the risk factors of BO. At the time of diagnosis, all BO patients had symptoms of cough and wheezing, and 10 (45.45%) had decreased exercise intolerance. Lung function showed moderate to severe obstructive ventilatory dysfunction, high-resolution computed tomography (HRCT) showed mosaic perfusion patterns. Multivariate binomial regression analysis showed that higher levels of serum lactate dehydrogenase (LDH) and hypoxemia were independent risk factors for BO after severe MP pneumonia. Higher levels of serum LDH and hypoxemia were independent risk factors for BO after severe MP pneumonia. For patients with risk factors, clinicians should regular follow-up for early diagnosis and intervention of BO.
Identifiants
pubmed: 35924019
doi: 10.2147/IDR.S372940
pii: 372940
pmc: PMC9343175
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4101-4108Informations de copyright
© 2022 Zheng et al.
Déclaration de conflit d'intérêts
The authors have no relevant financial or non-financial interests to disclose.
Références
Front Microbiol. 2016 Mar 31;7:414
pubmed: 27065977
Pediatr Neonatol. 2018 Oct;59(5):501-506
pubmed: 29337082
J Infect Chemother. 2014 Apr;20(4):270-3
pubmed: 24486173
Korean J Pediatr. 2015 Dec;58(12):459-65
pubmed: 26770220
Pediatr Pulmonol. 2019 Feb;54(2):212-219
pubmed: 30548423
Clin Pediatr (Phila). 2014 Dec;53(14):1409-12
pubmed: 25022946
Glob Pediatr Health. 2019 Apr 09;6:2333794X19840357
pubmed: 31008153
Front Pediatr. 2021 Sep 28;9:722885
pubmed: 34650942
Exp Ther Med. 2015 Jun;9(6):2379-2383
pubmed: 26136991
Influenza Other Respir Viruses. 2018 Jan;12(1):153-160
pubmed: 29460423
Pediatr Pulmonol. 2009 May;44(5):450-6
pubmed: 19360848
Int J Infect Dis. 2019 Mar;80:115-117
pubmed: 30634044
Respir Res. 2019 Aug 23;20(1):193
pubmed: 31443650
Sci Rep. 2017 Aug 16;7(1):8478
pubmed: 28814783
Zhonghua Er Ke Za Zhi. 2013 Nov;51(11):856-62
pubmed: 24484563
Respir Med. 2020 Dec;175:106209
pubmed: 33186845
Gigascience. 2019 Aug 1;8(8):
pubmed: 31367746
Curr Opin Pediatr. 2008 Jun;20(3):272-8
pubmed: 18475095
Zhonghua Er Ke Za Zhi. 2012 Oct;50(10):743-5
pubmed: 23302561
Springerplus. 2016 Sep 20;5(1):1622
pubmed: 27722041
Thorax. 2006 Jun;61(6):503-6
pubmed: 16517579
Respir Care. 2015 Oct;60(10):1469-75
pubmed: 26060318